oxidopamine

Summary

Summary: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.

Top Publications

  1. ncbi CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury
    T Schallert
    Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Mezes 330, Austin, TX 78712, USA
    Neuropharmacology 39:777-87. 2000
  2. ncbi Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research
    Yuen Ting Cheung
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    Neurotoxicology 30:127-35. 2009
  3. ncbi Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway
    Ronald Deumens
    Department of Psychiatry and Neuropsychology, Brain and Behavior Institute, 6200 MD Maastricht, The Netherlands
    Exp Neurol 175:303-17. 2002
  4. pmc Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease
    Ruben K Dagda
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    Autophagy 4:770-82. 2008
  5. ncbi Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease
    Elizabeth J Ryu
    Department of Pathology, Center for Neurobiology and Behavior, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Neurosci 22:10690-8. 2002
  6. ncbi Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
    Andreas Schober
    Department of Neuroanatomy and IZN, University of Heidelberg, Im Neuenheimer Feld 307, 69120 Heidelberg, Germany
    Cell Tissue Res 318:215-24. 2004
  7. ncbi Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons
    William Andrew Holtz
    Anatomy and Neurobiology Department, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 278:19367-77. 2003
  8. ncbi Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies
    Fernanda Martins Lopes
    Department of Biochemistry, ICBS UFRGS, Porto Alegre RS, Brazil
    Brain Res 1337:85-94. 2010
  9. ncbi Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network
    P J Magill
    Medical Research Council Anatomical Neuropharmacology Unit, University of Oxford, Mansfield Road, Oxford OX1 3TH, UK
    Neuroscience 106:313-30. 2001
  10. ncbi Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease
    Lingling Lu
    Beijing Institute for Neuroscience, The Beijing Center of Neural Regeneration and Repairing, Capital University of Medical Sciences, 10 You anMen Wai Xitoutiao, Beijing 100054, P R China
    Brain Res Brain Res Protoc 15:46-51. 2005

Research Grants

Detail Information

Publications278 found, 100 shown here

  1. ncbi CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury
    T Schallert
    Department of Psychology and Institute for Neuroscience, University of Texas at Austin, Mezes 330, Austin, TX 78712, USA
    Neuropharmacology 39:777-87. 2000
    ..OP-1 showed a beneficial effect on limb use asymmetry in the cylinder test...
  2. ncbi Effects of all-trans-retinoic acid on human SH-SY5Y neuroblastoma as in vitro model in neurotoxicity research
    Yuen Ting Cheung
    Laboratory of Neurodegenerative Diseases, Department of Anatomy, The University of Hong Kong, Pokfulam, Hong Kong SAR, China
    Neurotoxicology 30:127-35. 2009
    ..As a result, the real toxicity cannot be revealed in RA-differentiated cells. Therefore, undifferentiated SH-SY5Y is more appropriate for studying neurotoxicity or neuroprotection in experimental Parkinson's disease research...
  3. ncbi Modeling Parkinson's disease in rats: an evaluation of 6-OHDA lesions of the nigrostriatal pathway
    Ronald Deumens
    Department of Psychiatry and Neuropsychology, Brain and Behavior Institute, 6200 MD Maastricht, The Netherlands
    Exp Neurol 175:303-17. 2002
    ..The choice of the behavioral parameters determines the use of unilateral or bilateral lesions, although it is obvious that the bilateral model mimics the human situation more closely...
  4. pmc Mitochondrially localized ERK2 regulates mitophagy and autophagic cell stress: implications for Parkinson's disease
    Ruben K Dagda
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    Autophagy 4:770-82. 2008
    ..These data indicate that mitochondrial localization of ERK2 activity is sufficient to recapitulate the effects of 6-OHDA on mitophagy and autophagic cell death...
  5. ncbi Endoplasmic reticulum stress and the unfolded protein response in cellular models of Parkinson's disease
    Elizabeth J Ryu
    Department of Pathology, Center for Neurobiology and Behavior, Taub Institute for Research on Alzheimer s Disease and the Aging Brain, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    J Neurosci 22:10690-8. 2002
    ..Our findings, coupled with evidence from familial forms of Parkinson's disease, raise the possibility of widespread involvement of endoplasmic reticulum stress and the unfolded protein response in the pathophysiology of this disease...
  6. ncbi Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP
    Andreas Schober
    Department of Neuroanatomy and IZN, University of Heidelberg, Im Neuenheimer Feld 307, 69120 Heidelberg, Germany
    Cell Tissue Res 318:215-24. 2004
    ..The new genetic and environmental toxin models of PD (e.show $132#g. rotenone, paraquat, maneb) are discussed elsewhere in this "special issue."..
  7. ncbi Parkinsonian mimetics induce aspects of unfolded protein response in death of dopaminergic neurons
    William Andrew Holtz
    Anatomy and Neurobiology Department, Washington University School of Medicine, St Louis, Missouri 63110, USA
    J Biol Chem 278:19367-77. 2003
    ..The involvement of UPR in these widely used neurotoxin models supports the role of ubiquitin-proteasome pathway dysfunction in PD...
  8. ncbi Comparison between proliferative and neuron-like SH-SY5Y cells as an in vitro model for Parkinson disease studies
    Fernanda Martins Lopes
    Department of Biochemistry, ICBS UFRGS, Porto Alegre RS, Brazil
    Brain Res 1337:85-94. 2010
    ..Our data suggest that SH-SY5Y cells differentiated by 7 days with the protocol described here represent a more suitable experimental model for studying the molecular and cellular mechanisms underlying the pathophysiology of PD...
  9. ncbi Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network
    P J Magill
    Medical Research Council Anatomical Neuropharmacology Unit, University of Oxford, Mansfield Road, Oxford OX1 3TH, UK
    Neuroscience 106:313-30. 2001
    ..Furthermore, the relative contribution of rate and pattern to aberrant information coding is intimately related to the state of activation of the cerebral cortex...
  10. ncbi Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease
    Lingling Lu
    Beijing Institute for Neuroscience, The Beijing Center of Neural Regeneration and Repairing, Capital University of Medical Sciences, 10 You anMen Wai Xitoutiao, Beijing 100054, P R China
    Brain Res Brain Res Protoc 15:46-51. 2005
    ..05). All the data demonstrated that MSCs could readily be genetically engineered. Therefore, MSCs could be useful gene delivery vehicles of gene therapy for Parkinson's disease...
  11. ncbi 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta
    Katharine Hanrott
    Department of Biology and Biochemistry, University of Bath, 4 South, Claverton Down, Bath BA2 7AY, United Kingdom
    J Biol Chem 281:5373-82. 2006
    ....
  12. ncbi Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease
    M Lundblad
    Department of Physiological Sciences, Wallenberg Neuroscience Centre, Neurobiology Division, Lund University, BMC A11, S 221 84 Lund, Sweden
    Eur J Neurosci 15:120-32. 2002
    ..Such deficits can be quantified using novel and relatively simple testing procedures, whereas rotometry cannot discriminate between dyskinetic and antiakinetic effects of antiparkinsonian treatments...
  13. pmc Parkinsonian beta oscillations in the external globus pallidus and their relationship with subthalamic nucleus activity
    Nicolas Mallet
    Medical Research Council Anatomical Neuropharmacology Unit, University of Oxford, Oxford OX1 3TH, UK
    J Neurosci 28:14245-58. 2008
    ....
  14. ncbi Characterization of behavioral and neurodegenerative changes following partial lesions of the nigrostriatal dopamine system induced by intrastriatal 6-hydroxydopamine in the rat
    D Kirik
    Department of Physiology and Neuroscience, Lund University, Solvegatan 17, Lund, 223 62, Sweden
    Exp Neurol 152:259-77. 1998
    ....
  15. ncbi Nonhuman primate models of Parkinson's disease
    Marina E Emborg
    Preclinical Parkinson s Research Program, Wisconsin National Primate Research Center, University of Wisconsin Madison, 1223 Capitol Court, Madison, WI 53715, USA
    ILAR J 48:339-55. 2007
    ..Adequate experimental designs, with multiple outcome measures of clinical relevance and an appropriate number of animals, are essential to minimize the limitations of models and increase their predictive clinical validity...
  16. ncbi Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine
    R W Rodrigues
    Laboratory of Neuroregeneration, Department of Anatomy, Institute of Biomedical Sciences, , Av. Prof. Lineu Prestes, , Brazil
    Int J Neurosci 109:91-126. 2001
    ..The interaction between activated glial cells may be involved in the wounding and repair events in the partial lesioned nigrostriatal system as well as in the paracrine responses to surviving dopamine neurons...
  17. ncbi Contribution of pre-synaptic mechanisms to L-DOPA-induced dyskinesia
    M Carta
    Neurobiology Unit, Department of Experimental Medical Science, Lund University, BMC A11, Solvegatan 17, 22184 Lund, Sweden
    Neuroscience 198:245-51. 2011
    ....
  18. ncbi Liver growth factor promotes the survival of grafted neural stem cells in a rat model of Parkinson's disease
    Diana Reimers
    Servicio de Neurobiologia, Hospital Ramon y Cajal, Madrid, Spain
    Curr Stem Cell Res Ther 7:15-25. 2012
    ....
  19. ncbi Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease
    D Kirik
    Wallenberg Neuroscience Center, Department of Physiological Sciences, Lund University, BMC A11, 221 84 Lund, Sweden
    Eur J Neurosci 13:1589-99. 2001
    ....
  20. ncbi 6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease
    H Elkon
    Felsenstein Medical Research Center and the Department of Neurology, Rabin Medical Center, Tel Aviv University, Petah Tikva, Israel
    Cell Mol Neurobiol 21:771-81. 2001
    ..In conclusion, our findings suggest that 6-OHDA toxicity is associated with protein degradation and ubiquitin-proteasome system activation...
  21. ncbi Early transplantation of an encapsulated glial cell line-derived neurotrophic factor-producing cell demonstrating strong neuroprotective effects in a rat model of Parkinson disease
    Takao Yasuhara
    Department of Neurological Surgery, Okayama University Graduate School of Medicine and Dentistry, Okayama, Japan
    J Neurosurg 102:80-9. 2005
    ..The authors investigated the effects of GDNF on 6-hydroxydopamine (6-OHDA)-treated dopaminergic neurons in vitro and in vivo...
  22. ncbi Intrastriatal administration of erythropoietin protects dopaminergic neurons and improves neurobehavioral outcome in a rat model of Parkinson's disease
    Y Q Xue
    Department of Cellular Biology and Anatomy, Louisiana State University Health Sciences Center, 1501 Kings Highway, Shreveport, LA 71130, USA
    Neuroscience 146:1245-58. 2007
    ..Anti-inflammation may be one of mechanisms responsible for rhEPO neuroprotection...
  23. pmc Alterations in bioenergetic function induced by Parkinson's disease mimetic compounds: lack of correlation with superoxide generation
    Brian P Dranka
    Department of Biophysics and Free Radical Research Center, Medical College of Wisconsin, Milwaukee, WI, USA
    J Neurochem 122:941-51. 2012
    ..Together these data indicate that MPP(+), rotenone, and 6-OHDA dramatically shift bioenergetic function away from the mitochondria and towards glycolysis in N27 cells...
  24. ncbi Isoliquiritigenin isolated from licorice Glycyrrhiza uralensis prevents 6-hydroxydopamine-induced apoptosis in dopaminergic neurons
    Cheol Kyu Hwang
    Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA
    Biosci Biotechnol Biochem 76:536-43. 2012
    ..These results provide the first evidence that ISL can protect dopaminergic cells under oxidative stress conditions by regulating the apoptotic process...
  25. ncbi Comparative effects of acute or chronic administration of levodopa to 6-OHDA-lesioned rats on the expression and phosphorylation of N-methyl-D-aspartate receptor NR1 subunits in the striatum
    Min Kong
    Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine, 1665 Kongjiang Road, 200092 Shanghai, People s Republic of China
    Neurochem Res 34:1513-21. 2009
    ..Activated NMDA receptor NR1-mediated mechanisms are involved in the persistent expression of the motor response alterations that appear during chronic levodopa therapy of parkinsonian rats and continue after treatment withdrawal...
  26. ncbi Neuroprotective and neurorescue effect of black tea extract in 6-hydroxydopamine-lesioned rat model of Parkinson's disease
    R K Chaturvedi
    Developmental Toxicology Division, Industrial Toxicology Research Centre, Post Box 80, M G Marg Lucknow 226001, India
    Neurobiol Dis 22:421-34. 2006
    ....
  27. ncbi Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease
    Giovanna Levandis
    Laboratory of Functional Neurochemistry, Interdepartmental Research Center for Parkinsons s Disease CRIMP, IRCCS C Mondino, Pavia, Italy
    Neurobiol Dis 29:161-8. 2008
    ..Our data confirm the role of glutamatergic neurotransmission in the pathogenesis of dyskinesias and the potential of mGluR5 antagonists in the treatment of l-DOPA-induced dyskinesias...
  28. ncbi Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat
    S Walsh
    Department of Pharmacology and Therapeutics, National University of Ireland, Galway, Ireland
    Neuroscience 175:251-61. 2011
    ....
  29. pmc Protective effect of hydrogen sulphide against 6-OHDA-induced cell injury in SH-SY5Y cells involves PKC/PI3K/Akt pathway
    Chi Xin Tiong
    Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    Br J Pharmacol 161:467-80. 2010
    ....
  30. pmc Differentiation and transcription factor gene therapy in experimental parkinson's disease: sonic hedgehog and Gli-1, but not Nurr-1, protect nigrostriatal cell bodies from 6-OHDA-induced neurodegeneration
    A Hurtado-Lorenzo
    Gene Therapeutics Research Institute, Cedars Sinai Medical Center, Los Angeles, CA 90048 USA
    Mol Ther 10:507-24. 2004
    ..Differentiation and transcription factors can thus be used for the treatment of neurodegeneration by gene therapy...
  31. ncbi Neuroprotective effects of hydrogen sulfide on Parkinson's disease rat models
    Li Fang Hu
    Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
    Aging Cell 9:135-46. 2010
    ....
  32. ncbi Subthalamic GAD gene therapy in a Parkinson's disease rat model
    Jia Luo
    Functional Genomics and Translational Neuroscience Laboratory, Department of Molecular Medicine and Pathology, University of Auckland, Auckland, New Zealand
    Science 298:425-9. 2002
    ..This strategy suggests that there is plasticity between excitatory and inhibitory neurotransmission in the mammalian brain that could be exploited for therapeutic benefit...
  33. pmc Neuroinflammation mediated by IL-1beta increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease
    James B Koprich
    Center for Neuroregeneration Research, Harvard Medical School McLean Hospital, Belmont, MA 02478, USA
    J Neuroinflammation 5:8. 2008
    ..It is more likely that multiple factors converge to give rise to PD than any single cause. Here we report that inflammation can trigger degeneration of dopamine (DA) neurons in an animal model of Parkinson's disease...
  34. pmc Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model
    Lars M Bjorklund
    Udall Parkinson s Disease Research Center of Excellence, Neuroregeneration Laboratories, and Molecular Neurobiology Laboratory, McLean Hospital Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Proc Natl Acad Sci U S A 99:2344-9. 2002
    ..These results demonstrate that transplanted ES cells can develop spontaneously into DA neurons. Such DA neurons can restore cerebral function and behavior in an animal model of Parkinson's disease...
  35. pmc Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss
    Bonnie G Garcia
    Department of Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37212, USA
    Cereb Cortex 20:2423-32. 2010
    ..These studies provide the first evidence to show that MSN spine loss associated with parkinsonism can be reversed and point to suppression of corticostriatal glutamate release as a means of slowing progression in Parkinson's disease...
  36. ncbi Downregulation of glial glutamate transporters after dopamine denervation in the striatum of 6-hydroxydopamine-lesioned rats
    E K Y Chung
    Department of Biology, Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
    J Comp Neurol 511:421-37. 2008
    ..These results indicate that there are differential and distinct modulations of glutamate transporters after dopamine denervation in the 6-hydroxydopamine-lesioned rat...
  37. ncbi MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats
    Nadine Jonkers
    Department of Pharmaceutical Chemistry and Drug Analysis, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
    Brain Res 926:149-55. 2002
    ..The suppression of this increase by prior administration of MK801 could represent a neuroprotective effect...
  38. ncbi Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats
    Véronique Sgambato-Faure
    INSERM U318, Laboratoire de Neurosciences Précliniques, CHU Pavillon B, Grenoble, France
    J Neuropathol Exp Neurol 64:936-47. 2005
    ....
  39. ncbi Striatal deafferentation increases dopaminergic neurogenesis in the adult olfactory bulb
    Beate Winner
    Department of Neurology, University of Regensburg, Regensburg, Germany
    Exp Neurol 197:113-21. 2006
    ..This study supports the accumulating evidence that neurotransmitters play a crucial role in determining survival and differentiation of newly generated neurons...
  40. ncbi Dopamine depletion impairs precursor cell proliferation in Parkinson disease
    Günter U Höglinger
    INSERM U289 Hôpital de la Salpetrière, F 75651 Paris, France
    Nat Neurosci 7:726-35. 2004
    ..These observations suggest that the generation of neural precursor cells is impaired in Parkinson disease as a consequence of dopaminergic denervation...
  41. ncbi "Passive stabilization" of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6-OHDA-lesioned rat
    Brian P Bergstrom
    Department of Biology, Muskingum College, New Concord, Ohio, USA
    J Neurochem 87:1224-36. 2003
    ....
  42. ncbi Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations
    Marcelo Machado Ferro
    Departamento de Farmacologia, Universidade Federal do Parana, Curitiba, Brazil
    J Neurosci Methods 148:78-87. 2005
    ..The picture of mild motor effects and robust impairment of habit learning and spatial working memory observed in MPTP-lesioned rats models the early phase of Parkinson's disease...
  43. ncbi Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum
    Y He
    Department of Neurology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Brain Res 909:187-93. 2001
    ..All these results suggest that microglial activation may be involved in the nigral cell degeneration in 6-OHDA induced parkinsonian mice...
  44. ncbi 6-Hydroxydopamine toxicity towards human SH-SY5Y dopaminergic neuroblastoma cells: independent of mitochondrial energy metabolism
    A Storch
    Department of Neurology, University of Ulm Medical School, Federal Republic of Germany
    J Neural Transm 107:281-93. 2000
    ..These results suggest that cell death induced by 6-OHDA is not due to an inhibition of mitochondrial energy supply, but probably involves production of free radicals...
  45. ncbi Lesions of dopaminergic neurons in the substantia nigra pars compacta and in the ventral tegmental area enhance depressive-like behavior in rats
    Christine Winter
    Department of Psychiatry and Psychotherapy, Charite Campus Mitte, Germany
    Behav Brain Res 184:133-41. 2007
    ..The effects of citalopram administration on depressive behavior induced by lesions of dopaminergic brain regions furthermore suggest an involvement of serotonergic pathways in dopaminergic cell loss-induced depression...
  46. pmc Treatment with a substance P receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early Parkinson's disease
    Emma Thornton
    Adelaide Centre for Neuroscience Research, School of Medical Sciences, The University of Adelaide, Adelaide, South Australia
    PLoS ONE 7:e34138. 2012
    ..We propose that neurogenic inflammation contributes to dopaminergic degeneration in early experimental PD and demonstrate that an NK1 receptor antagonist may represent a novel neuroprotective therapy...
  47. ncbi Intrastriatal botulinum toxin abolishes pathologic rotational behaviour and induces axonal varicosities in the 6-OHDA rat model of Parkinson's disease
    Andreas Wree
    Department of Anatomy, University of Rostock, Gertrudenstr 9, 18057 Rostock, Germany
    Neurobiol Dis 41:291-8. 2011
    ..Intrastriatal application of BoNT-A may antagonize localized relative functional disinhibited hypercholinergic activity in neurodegenerative diseases such as PD avoiding side effects of systemic anti-cholinergic treatment...
  48. ncbi C-terminal mechano-growth factor induces heme oxygenase-1-mediated neuroprotection of SH-SY5Y cells via the protein kinase Cϵ/Nrf2 pathway
    Arnulfo Quesada
    Department of Neurobiology, David Geffen School of Medicine at the University of California at Los Angeles, Los Angeles, California, USA
    J Neurosci Res 89:394-405. 2011
    ....
  49. ncbi Arylpiperazine-mediated activation of Akt protects SH-SY5Y neuroblastoma cells from 6-hydroxydopamine-induced apoptotic and autophagic death
    Gordana Tovilovic
    Institute for Biological Research, University of Belgrade, Despota Stefana Blvd 142, 11000 Belgrade, Serbia
    Neuropharmacology 72:224-35. 2013
    ..Because of the ability to prevent 6-OHDA induced apoptotic/autophagic cell death through activation of Akt, the investigated arylpiperazines could be potential candidates for treatment of neurodegenerative diseases...
  50. ncbi Mechanism of 6-hydroxydopamine neurotoxicity: the role of NADPH oxidase and microglial activation in 6-hydroxydopamine-induced degeneration of dopaminergic neurons
    J Rodriguez-Pallares
    Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain
    J Neurochem 103:145-56. 2007
    ....
  51. pmc Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains
    Jason Callio
    Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    J Biol Chem 280:18536-42. 2005
    ..Antioxidant therapies that target this subcellular compartment may prove promising...
  52. ncbi Autophagy-dependent and -independent involvement of AMP-activated protein kinase in 6-hydroxydopamine toxicity to SH-SY5Y neuroblastoma cells
    Katarina Arsikin
    Institute of Microbiology and Immunology, School of Medicine, University of Belgrade, Dr Subotica 1, 11000 Belgrade, Serbia
    Biochim Biophys Acta 1822:1826-36. 2012
    ..These data suggest that oxidative stress-mediated AMPK/mTOR-dependent autophagy and AMPK/p38-dependent apoptosis could be valid therapeutic targets for neuroprotection...
  53. ncbi Serotonin 1B receptor stimulation reduces D1 receptor agonist-induced dyskinesia
    Karen L Eskow Jaunarajs
    Department of Psychology, Binghamton University, State University of New York, Binghamton, New York 13902, USA
    Neuroreport 20:1265-9. 2009
    ..These findings suggest that 5-HT1B receptor stimulation directly diminishes D1 receptor-mediated dyskinesia, implicating an important target for the treatment of L-DOPA-induced dyskinesia...
  54. pmc 6-Hydroxydopamine induces mitochondrial ERK activation
    Scott M Kulich
    Department of Pathology, VA Pittsburgh Healthcare System, Pittsburgh, PA 15240, USA
    Free Radic Biol Med 43:372-83. 2007
    ....
  55. ncbi Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease
    Christopher Kobylecki
    Faculty of Life Sciences, University of Manchester, Manchester, UK
    J Neurochem 114:499-511. 2010
    ..These data suggest that Ca(2+)-permeable AMPA receptors are critically involved in both the induction and subsequent expression of LID, and represent a potential target for anti-dyskinetic therapies...
  56. ncbi Partial lesion of the dopaminergic innervation of the ventral striatum induces "depressive-like" behavior of rats
    Katarzyna Kuter
    Department of Neuro Psychopharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12, Pl 31 343 Krakow, Poland
    Pharmacol Rep 63:1383-92. 2011
    ..The present study indicates that a relatively small lesion of dopaminergic terminals in the ventral striatum, which does not produce any motor disturbances, may induce "depressive-like" symptoms...
  57. ncbi Gene expression profiles of reactive astrocytes in dopamine-depleted striatum
    Takao Nakagawa
    Neurotrophic Factors Section, National Institute of Neurological Disorders and Stroke, NIH, DHHS, Bethesda, MD, USA
    Brain Pathol 14:275-80. 2004
    ..Understanding these gene differences that occur in astrocytes in response to dopamine depletion should enhance our ability to promote recovery from the injury...
  58. ncbi Survival and early functional integration of dopaminergic progenitor cells following transplantation in a rat model of Parkinson's disease
    Michaela Hahn
    Department of Stereotactic and Functional Neurosurgery, Albert Ludwigs University, Freiburg, Germany
    J Neurosci Res 87:2006-19. 2009
    ..These data highlight the complexity of graft-host interactions and provide novel insights into the dynamics of DA progenitor graft-mediated functional recovery in animal models of Parkinson's disease...
  59. ncbi Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons
    N Lindefors
    Department of Pharmacology, Karolinska Institutet, Stockholm, Sweden
    Neurosci Lett 115:248-52. 1990
    ..The results indicate that mesencephalic dopamine neurons regulate neuronal glutamate in ipsilateral as well as contralateral caudate-putamen...
  60. ncbi Differential astroglial activation in 6-hydroxydopamine models of Parkinson's disease
    Jeannette Henning
    Department of Neurology, University of Rostock, Germany
    Neurosci Res 62:246-53. 2008
    ....
  61. ncbi BN82451 attenuates L-dopa-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease
    Brigitte Spinnewyn
    Ipsen Innovation, Neurology, Les Ulis, France
    Neuropharmacology 60:692-700. 2011
    ..The data demonstrate that BN82451 effectively attenuates LID and the associated molecular alterations in an animal model of PD and may represent a treatment option for managing dyskinesia...
  62. ncbi Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease
    Isabel Lastres-Becker
    Departamento de Bioquimica y Biologia Molecular III, Facultad de Medicina, Universidad Complutense, 28040 Madrid, Spain
    Neurobiol Dis 19:96-107. 2005
    ....
  63. ncbi Evaluation of the neurotoxic/neuroprotective role of organoselenides using differentiated human neuroblastoma SH-SY5Y cell line challenged with 6-hydroxydopamine
    Fernanda Martins Lopes
    Departamento de Bioquimica, Laboratório 24, ICBS Universidade Federal do Rio Grande do Sul UFRGS, Porto Alegre, RS 90035 003, Brazil
    Neurotox Res 22:138-49. 2012
    ....
  64. ncbi Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease
    Eunju Shin
    Wallenberg Neuroscience Center, Division of Neurobiology, Lund University, Lund, Sweden
    Neurobiol Dis 47:393-406. 2012
    ..Together, these results point to a critical role of both 5-HT(1) and D(2) receptors in the modulation of GID, and suggest that 5-HT neurons exert a modulatory role in the development of this side effect of neuronal transplantation...
  65. ncbi Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: motor impairments identify extent of dopamine depletion at three different lesion sites
    Andreas Heuer
    Brain Repair Group, School of Bioscience, Cardiff University, Cardiff, Wales, UK
    Behav Brain Res 228:30-43. 2012
    ....
  66. ncbi Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine
    Ronise M Santiago
    Laboratorio de Fisiologia e Farmacologia do Sistema Nervoso Central, Departamento de Farmacologia, Universidade Federal do Parana, Curitiba, PR, Brasil
    Prog Neuropsychopharmacol Biol Psychiatry 34:1104-14. 2010
    ..Moreover, DA and 5-HT strongly correlated with "emotional" impairments suggesting an important participation of these neurotransmitters in anhedonia and behavioral despair after nigral lesions promoted by the neurotoxins...
  67. ncbi Therapeutic doses of L-dopa reverse hypersensitivity of corticostriatal D2-dopamine receptors and glutamatergic overactivity in experimental parkinsonism
    Barbara Picconi
    Dipartimento di Neuroscienze, Clinica Neurologica, Universita di Roma Tor Vergata, Rome, Italy
    Brain 127:1661-9. 2004
    ....
  68. ncbi Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat
    S Singh
    Department of Physiology, Maulana Azad Medical College, New Delhi, India
    Indian J Med Res 124:419-26. 2006
    ..Therefore in the present study the effect of neuroprotectory melatonin was tested against 6-hydroxydopamine (6-OHDA) neurotoxicity for striatal dopaminergic neurons in the rat...
  69. ncbi Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease
    Naomi P Visanji
    Toronto Western Research Institute, 399 Bathurst Street, MC11 419, Toronto, Ontario M5T 2S8, Canada
    Neurobiol Dis 35:184-92. 2009
    ..Our data suggest a role for D3 receptors in the development of LID and suggest that initiating L-DOPA treatment with a D3 antagonist may reduce the development of LID in PD...
  70. pmc High-frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l-3,4-dihydroxyphenylalanine in dopaminergic denervated rats
    Emilie Lacombe
    Institut National de la Sante et de la Recherche Medicale, Unite 836, Grenoble Institut des Neurosciences, Equipe Dynamique des Réseaux Neuronaux du Mouvement, Grenoble, France
    Eur J Neurosci 26:1670-80. 2007
    ..These new neurochemical data suggest that STN-HFS interferes with L-DOPA effects, probably synergically, by stabilizing dopamine levels in the striatum and shed light on the mechanisms of STN-HFS in PD...
  71. ncbi Non-dopaminergic neurons in ventral mesencephalic transplants make widespread axonal connections in the host brain
    Lachlan H Thompson
    Division of Neurobiology, Wallenberg Neuroscience Center, Department of Experimental Medical Science, Lund University, S 22184 Lund, Sweden
    Exp Neurol 213:220-8. 2008
    ....
  72. pmc Functional reorganization of the presynaptic dopaminergic terminal in parkinsonism
    B P Bergstrom
    Department of Biology, Neuroscience Program, Muskingum University, New Concord, OH 43762, USA
    Neuroscience 193:310-22. 2011
    ..This novel neuroadaptation may contribute to early preclinical normalization of function and help resolve discrepant findings regarding compensatory changes in DA release during progression of the parkinsonian state...
  73. ncbi Impaired acquisition of skilled behavior in rotarod task by moderate depletion of striatal dopamine in a pre-symptomatic stage model of Parkinson's disease
    Taichi Ogura
    Division of Brain Science, Graduate School of Medical Science, Kitasato University, Sagamihara 228 8555, Japan
    Neurosci Res 51:299-308. 2005
    ..Based on these results, we concluded that the striatum-based function underlying the acquisition of skilled behaviors or sensorimotor learning may be more vulnerable to dopamine depletion than the motor control...
  74. ncbi Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions
    L Truong
    Department of Pharmacology, Institute for Biochemical Research, Bosch Building, School of Medical Sciences, University of Sydney, NSW 2006, Australia
    Behav Brain Res 169:1-9. 2006
    ..This graded model can be useful for testing potential neuroprotective compounds for PD...
  75. ncbi Differential expression and ser897 phosphorylation of striatal N-methyl-d-aspartate receptor subunit NR1 in animal models of Parkinson's disease
    Ranjita Betarbet
    Department of Neurology and the Center for Neurodegenerative Disease, Emory University, Atlanta GA 30322, USA
    Exp Neurol 187:76-85. 2004
    ..Furthermore, the alterations observed in protein kinase A-dependent phosphorylation of NR1 are suggestive of receptor internalization and subcellular trafficking of NR1 in response to increased striatal glutamatergic activity...
  76. ncbi Early inhibition of TNFalpha increases 6-hydroxydopamine-induced striatal degeneration
    Carmelina Gemma
    James A Haley Veterans Administration Hospital, Tampa, FL, USA
    Brain Res 1147:240-7. 2007
    ..These findings suggest that TNF release is neuroprotective in the early stages of injury but becomes neurotoxic when chronically induced...
  77. ncbi Electrophysiological characterization of substantia nigra dopaminergic neurons in partially lesioned rats: effects of subthalamotomy and levodopa treatment
    Gaizka Bilbao
    Department of Neurosurgery, Cruces Hospital E 48903, Bizkaia, Spain
    Brain Res 1084:175-84. 2006
    ..In this model, subthalamotomy does not modify the firing pattern while levodopa treatment efficiently restores normal firing of SNpc neurons and does not appear to be toxic to them...
  78. ncbi Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease
    Marie Therese Armentero
    Laboratory of Functional Neurochemistry, IRCCS Neurological Institute C Mondino, Via Mondino, 2, 27100 Pavia, Italy
    Neurobiol Dis 22:1-9. 2006
    ..Specific modulation of STN hyperactivity obtained with mGluR5 blockade may, therefore, open interesting perspectives for the use of this class of compounds in the treatment of Parkinson's disease...
  79. ncbi Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death
    Barbara Monti
    Department of Biology, University of Bologna, Bologna, Italy
    J Neurochem 103:518-30. 2007
    ..These results are relevant to more precisely define the role of alpha-synuclein in neuronal cells and to better understand its putative involvement in neurodegeneration...
  80. pmc Dissociable roles of dopamine within the core and medial shell of the nucleus accumbens in memory for objects and place
    Andrew J D Nelson
    School of Psychology, University of Nottingham, Nottingham, England
    Behav Neurosci 124:789-99. 2010
    ..These results suggest that dopamine function within distinct subregions of the NAc plays dissociable roles in the modulation of memory for objects and place...
  81. ncbi Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease
    M T Tadaiesky
    Departamento de Farmacologia, Centro de Ciencias Biologicas, Universidade Federal de Santa Catarina, UFSC, Campus Universitario, Trindade, Florianopolis, SC, Brazil
    Neuroscience 156:830-40. 2008
    ....
  82. ncbi Partial recovery of dopaminergic pathway after graft of adult mesenchymal stem cells in a rat model of Parkinson's disease
    Gaëlle Bouchez
    INSERM U930, Laboratory Biophysique médicale and pharmaceutique, UFR Pharmacie, 31 Avenue Monge, Tours, France
    Neurochem Int 52:1332-42. 2008
    ..This cellular approach might be a restorative therapy in Parkinson's disease...
  83. ncbi Effects of GDNF on 6-OHDA-induced death in a dopaminergic cell line: modulation by inhibitors of PI3 kinase and MEK
    Susana D Ugarte
    Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania 15213, USA
    J Neurosci Res 73:105-12. 2003
    ..These studies suggest that GDNF can protect dopaminergic cells against some but not all aspects of 6-OHDA-induced toxicity by acting through both PI3K and MAPK signaling pathways...
  84. ncbi Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats
    Diana Reimers
    Servicio de Neurobiologia, Hospital Ramon y Cajal, 28034 Madrid, Spain
    J Histochem Cytochem 54:457-65. 2006
    ..As apomorphine-induced rotational behavior was also reduced in these animals, we propose LGF as a novel factor that, when delivered to the striatum, may be useful in the treatment of Parkinson's disease...
  85. ncbi Ciliary neurotrophic factor mediates dopamine D2 receptor-induced CNS neurogenesis in adult mice
    Peng Yang
    Kentucky Spinal Cord Injury Research Center and Department of Neurological Surgery, University of Louisville, Louisville, Kentucky 40292, USA
    J Neurosci 28:2231-41. 2008
    ..Because CNTF is predominantly expressed in the nervous system, this mechanism and the ability to pharmacologically modulate it have implications for Parkinson's disease and cell-replacement therapies for other disorders...
  86. ncbi Serotonergic neurons mediate ectopic release of dopamine induced by L-DOPA in a rat model of Parkinson's disease
    Sylvia Navailles
    Universite de Bordeaux, Unité Mixte de Recherche Centre National de la Recherche Scientifique 5227, Centre Hospitalier Universitaire de Bordeaux, 33076 Bordeaux Cedex, France
    Neurobiol Dis 38:136-43. 2010
    ..These data demonstrate that l-DOPA induces an ectopic release of dopamine due to serotonergic neurons. The new pattern of dopamine transmission created by l-DOPA may contribute to the benefit and side effects of l-DOPA...
  87. ncbi Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice
    Ruxandra Iancu
    Neuronal Survival Unit, Wallenberg Neuroscience Centre, Department of Experimental Medical Sciences, Lunds University, BMC A10, 22184 Lund, Sweden
    Behav Brain Res 162:1-10. 2005
    ..This mouse model offers the opportunity to use transgenic mouse strains and study the interactions between genes of interest and toxins in relation to Parkinson's disease etiology in the future...
  88. ncbi Relationship between microglial activation and dopaminergic neuronal loss in the substantia nigra: a time course study in a 6-hydroxydopamine model of Parkinson's disease
    Lilia Marinova-Mutafchieva
    Parkinson s Disease Research Group, Department of Cellular and Molecular Neuroscience, Division of Neuroscience and Mental Health, Faculty of Medicine, Imperial College London, London, UK
    J Neurochem 110:966-75. 2009
    ..This study suggests that activation of microglia precedes DA neuronal cell loss and neurons undergoing degeneration may be phagocytosed prematurely by phagocytic microglia...
  89. ncbi Mesencephalic astrocyte-derived neurotrophic factor is neurorestorative in rat model of Parkinson's disease
    Merja H Voutilainen
    Division of Pharmacology and Toxicology, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland
    J Neurosci 29:9651-9. 2009
    ..Our results suggest that MANF is readily distributed throughout the striatum and has significant therapeutic potential for the treatment of PD...
  90. pmc Mobilization of neural stem cells and generation of new neurons in 6-OHDA-lesioned rats by intracerebroventricular infusion of liver growth factor
    Rafael Gonzalo-Gobernado
    Servicio de Neurobiologia, Hospital Ramon y Cajal, Carretera de Colmenar Km 9 1, 28034 Madrid, Spain
    J Histochem Cytochem 57:491-502. 2009
    ..Considering that this factor also promotes neuronal migration into damaged tissue, we propose LGF as a novel factor useful for neuronal replacement in neurodegenerative diseases...
  91. pmc Functional repression of cAMP response element in 6-hydroxydopamine-treated neuronal cells
    Elisabeth M Chalovich
    Department of Pathology, Division of Neuropathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
    J Biol Chem 281:17870-81. 2006
    ....
  92. ncbi Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain
    Z D Ling
    Department of Pharmacology, 1735 West Harrison Street, Room 410, Rush University Medical Center, Chicago, IL 60612, USA
    Neuroscience 124:619-28. 2004
    ..The results suggest that individuals exposed to LPS prenatally, as might occur had their mother had bacterial vaginosis, would be at increased risk for Parkinson's disease...
  93. ncbi 6-Hydroxydopamine lesion of the rat prefrontal cortex increases locomotor activity, impairs acquisition of delayed alternation tasks, but does not affect uninterrupted tasks in the radial maze
    M Bubser
    Universitat Tubingen, Abteilung Neuropharmakologie, F R G
    Behav Brain Res 37:157-68. 1990
    ....
  94. ncbi Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease
    Hong Yuan
    Department of Pharmaceutical Chemistry and Drug Analysis, Research Group Experimental Pharmacology, Vrije Universiteit Brussel, Laarbeeklaan 103, 1090 Brussels, Belgium
    J Neurosci Methods 144:35-45. 2005
    ..However, the partial denervation renders its quite suitable for mimicking early stage Parkinson's disease, and is thus suitable for testing possible neuroprotective and neurotrophic drugs...
  95. ncbi Subtype selective antagonism of substantia nigra pars compacta Group I metabotropic glutamate receptors protects the nigrostriatal system against 6-hydroxydopamine toxicity in vivo
    Anthony C Vernon
    Department of Cellular and Molecular Neuroscience, Faculty of Medicine, Imperial College London, Charing Cross Campus, London, UK
    J Neurochem 103:1075-91. 2007
    ....
  96. ncbi Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging
    F Cicchetti
    Neuroregeneration Laboratory, MRC119, McLean Hospital Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
    Eur J Neurosci 15:991-8. 2002
    ..These data support the hypothesis that inflammation is a significant component of progressive dopaminergic degeneration that can be monitored by PET imaging...
  97. pmc Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors
    Maria Grazia Morgese
    Department of Biomedical Sciences, University of Foggia, Viale Luigi Pinto 1, 71100 Foggia, Italy
    Exp Neurol 208:110-9. 2007
    ..Our data indicate that pharmacological blockade of TRPV1 receptors unmasks the anti-dyskinetic effects of FAAH inhibitors and that CB(1) and TRPV1 receptors play opposite roles in levodopa-induced dyskinesias...
  98. ncbi Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease
    Ofer Sadan
    Laboratory of Neurosciences, Felsenstein Medical Research Center, Department of Neurology, Rabin Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    Stem Cells Dev 18:1179-90. 2009
    ..We therefore conclude that the induced MSC have a therapeutic potential for neurodegenerative processes and diseases, both by the NTFs secretion and by the migratory trait toward the diseased tissue...
  99. ncbi Timecourse of striatal re-innervation following lesions of dopaminergic SNpc neurons of the rat
    D Stanic
    Department of Medicine, Monash University, Monash Medical Centre, Clayton, Australia
    Eur J Neurosci 18:1175-88. 2003
    ..These studies provide insights into the processes that regulate sprouting responses in the central nervous system following injury...
  100. ncbi Blueberry- and spirulina-enriched diets enhance striatal dopamine recovery and induce a rapid, transient microglia activation after injury of the rat nigrostriatal dopamine system
    Ingrid Stromberg
    Department of Integrative Medical Biology, Umea University, S 901 87 Umea, Sweden
    Exp Neurol 196:298-307. 2005
    ..In conclusion, enhanced striatal dopamine recovery appeared in animals treated with diet enriched in antioxidants and anti-inflammatory phytochemicals and coincided with an early, transient increase in OX-6-positive microglia...
  101. ncbi Time-course of nigrostriatal damage, basal ganglia metabolic changes and behavioural alterations following intrastriatal injection of 6-hydroxydopamine in the rat: new clues from an old model
    Fabio Blandini
    Laboratory of Functional Neurochemistry, IRCCS Neurological Institute C Mondino, Pavia, Italy
    Eur J Neurosci 25:397-405. 2007
    ....

Research Grants65

  1. Dopamine D4 Receptor in Sustained Attention
    Kehong Zhang; Fiscal Year: 2003
    ..The findings may also provide a pharmacological basis for innovative treatment for ADHD to replace stimulant therapy. ..
  2. Effects of Stress on Pathology of Parkinson's Disease
    GERLINDE METZ; Fiscal Year: 2004
    ..These approaches will provide the opportunity to understand factors involved in the pathology of PD and to develop novel therapeutic strategies for neurodegenerative motor disorders. ..
  3. Molecular Basis of D1 and D2 Priming
    Alexia Pollack; Fiscal Year: 2003
    ..Elucidation of this mechanism could lead to treatment strategies aimed to prevent these dyskinesias, which would, in turn, lengthen the time that dopamine replacement therapy is effective to treat patients with PD. ..
  4. BASAL GANGLIA CIRCUITRY IMMEDIATE EARLY GENE EXPRESSION
    David Wirtshafter; Fiscal Year: 2003
    ..Other studies will examine the effects of lesions within the basal ganglia on the IEG expression induced by systemic administration of dopaminergic drugs. ..
  5. TRAINING FACULTY TO TEACH SURVIVAL SKILLS AND ETHICS
    Michael Zigmond; Fiscal Year: 2005
    ..Efforts will be made to promote diversity with regard to the demographics of both the workshop participants and those they serve. Instruction will be provided by the PI's together with a highly qualified group of trainers. ..
  6. Lateral Hypothalamus, Dopamine and Ingestive Behavior
    David Wirtshafter; Fiscal Year: 2007
    ..Gaining an understanding of these systems is a prerequisite for the rational development of novel treatments for disturbances of ingestion, such as occur in obesity, bulemia and cahchexia. [unreadable] [unreadable] [unreadable]..
  7. Developmental Stress and Vulnerability to Brain Injury
    Michael Zigmond; Fiscal Year: 2004
    ..Moreover, the methods and reagents that we develop will be made available to others in the field. ..
  8. AGING AND 6 HYDROXYDOPAMINE NEUROTOXICITY
    Wayne Cass; Fiscal Year: 2005
    ....
  9. Calcitriol and Methamphetamine Neurotoxicity
    Wayne Cass; Fiscal Year: 2008
    ..Furthermore, if calcitriol is effective, it could have therapeutic applications in other disease processes where there is a loss of monoamine neurons, such as in Parkinson's disease. [unreadable] [unreadable] [unreadable]..
  10. Development Stress, Exercise, and Vulnerability to Neuronal Injury
    Michael J Zigmond; Fiscal Year: 2010
    ....
  11. Calcitriol-Induced Restoration of Dopamine in a Model of Parkinson's Disease
    Wayne Cass; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  12. ADAPTIVE BEHAVIOR AND BRAIN MONOAMINES
    Michael Zigmond; Fiscal Year: 2002
    ..The longer-term objectives of this project are to provide new insights into the basic neurobiology of LC neurons and the psychopathology that develops from chronic stress. ..
  13. Environmental Toxicants and Neurodegeneration
    Kim Tieu; Fiscal Year: 2010
    ..In addition, these studies may provide significant insights into a novel mechanism that contributes to the pattern of cell death as seen in neurodegenerative disorders such as sporadic Parkinson's disease. ..
  14. Mechanisms underlying reward-related synaptogenesis
    Gloria E Meredith; Fiscal Year: 2010
    ..abstract_text> ..
  15. Flumazenil on Multiple Stress and Withdrawal Anxiety
    George Breese; Fiscal Year: 2007
    ....
  16. Imaging stem cell implants in neurodegenerative disease
    Lorraine Iacovitti; Fiscal Year: 2007
    ..This will provide vital information in the animal model of PD, allow us to longitudinally follow DA neuron regeneration, and, most importantly, will be translatable to clinical human studies using similar techniques. ..
  17. Mitochondrial respiratory uncoupling and the pathogenes*
    William Sivitz; Fiscal Year: 2006
    ..This is mediated by one or more UCP subtype. 4. Altered mitochondrial coupling and consequent changes in mitochondrial ROS formation alter endothelial cell generation of nitric oxide. ..
  18. The Rochester Center for Mind-Body Research
    Jan Moynihan; Fiscal Year: 2006
    ..By the end of the award period, we will be a mature, established Center with a submitted program project or Center grant application. ..
  19. Using Stem Cells in Animal Models of Parkinson's Disease
    Lorraine Iacovitti; Fiscal Year: 2006
    ..abstract_text> ..
  20. NEURAL CIRCUITRY OF SENSORIMOTOR GATING ACROSS SPECIES
    Neal Swerdlow; Fiscal Year: 2006
    ....
  21. Blood Brain Barrier Dysfunction in Parkinson's Diseases
    Paul M Carvey; Fiscal Year: 2010
    ..These findings would provide an entirely new hypothesis for progression pa hogenesis and identify new targets for therapeutic intervention in PD designed arou d affecting BBB integrity. ..
  22. TRANSCRIPTIONAL CONTROL OF NEUROENDOCRINE GENES
    KAREN O MALLEY; Fiscal Year: 2007
    ..Knowledge gained from these studies may offer new routes for therapeutic intervention. ..
  23. STUDIES OF PURIFIED DOPAMINE NEURONS
    Lorraine Iacovitti; Fiscal Year: 2007
    ..This work will hopefully lay the foundation for the development of therapeutic treatments for Parkinson's and other diseases involving compromised DA systems. ..
  24. MODULATION OF DOPAMINE AUTORECEPTOR FUNCTION BY COCAINE
    KAREN O MALLEY; Fiscal Year: 2001
    ..Taken together these studies will significantly extend our ongoing efforts to understand the complex receptor/presynaptic effector interactions involved in the reinforcing and behavioral sensitization effects of cocaine. ..
  25. Mindfulness to Improve Elders' Immune and Health Status
    Jan Moynihan; Fiscal Year: 2008
    ..The findings of this RCT will have implications for the conceptualization, refinement, and dissemination of psychosocial interventions aimed at slowing the rate of immunosenescence. ..
  26. Stress Sensitization of CRF-Induced Withdrawal Behaviors
    George Breese; Fiscal Year: 2009
    ..New treatment strategies could emerge from such knowledge ..
  27. Functional Consequences of Nuclear mGlu5 Receptor Activation
    KAREN O MALLEY; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  28. Neurophysiology and Biomechanics of Urethra in Stress Urinary Incontinence
    Naoki Yoshimura; Fiscal Year: 2008
    ..This is recognized as a high priority in the urologic/gynecologic care of SUI patients. [unreadable] [unreadable]..
  29. Hybrid Drugs: Novel Pharmacotherapy for ADHD
    FRANK TARAZI; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  30. NEUROPROTECTIVE STRATEGIES AGAINST OXIDATIVE DAMAGE
    Anumantha Kanthasamy; Fiscal Year: 2009
    ....
  31. Neurotrophic factors and HIV-mediated neuronal injury
    Italo Mocchetti; Fiscal Year: 2008
    ....
  32. APOPTOSIS IN SUBSTANTIA NIGRA
    Robert E Burke; Fiscal Year: 2010
    ..abstract_text> ..
  33. Chronic Alcohol & AIDS Impact on Muscle Wasting
    Patricia Molina; Fiscal Year: 2006
    ..abstract_text> ..
  34. Cytokine and MAP Kinase Involvement in Neuropathic Pain
    Linda Sorkin; Fiscal Year: 2008
    ..This approach has the potential for avoiding some of the problems that occur with complete inhibition of p38 function. ..
  35. Zebrafish Screen for Neuroprotective Anti-oxidants
    Chuenlei Parng; Fiscal Year: 2005
    ..Assessment of drug effects in a convenient vertebrate model, prior to evaluation in a complex system, such as mouse, can potentially streamline the drug development process and dramatically reduce costs. ..
  36. NOVEL USE OF ZEBRAFISH FOR APOPTOSIS ASSAY
    Chuenlei Parng; Fiscal Year: 2004
    ..Complementary visual and flow cytometry based assays will also be developed to provide comprehensive analysis of apoptosis in zebrafish. ..
  37. SCIENCE PARTNERSHIPS FOR HANDS-ON LEARNING -PHASE II
    Jan Moynihan; Fiscal Year: 2003
    ..Teachers will have use of a "lending library" of science equipment and supplies to perform activities in their classrooms. ..
  38. Chronic Ethanol Effects on CNS Opiate Receptors
    Linda Saland; Fiscal Year: 2003
    ..It will also be possible to study the functional changes that may occur in the receptors after withdrawal from consumption. A future potential may be then to target delta receptors for treating chronic alcoholism. ..
  39. Lower urinary tract dysfunction in Parkinson's disease
    Naoki Yoshimura; Fiscal Year: 2003
    ..This is a high priority in the urologic care of patients with Parkinson's disease. ..
  40. NEUROTOXINS, NEURAL INJURY AND OBESITY
    Pushpa Kalra; Fiscal Year: 2003
    ..abstract_text> ..
  41. MOLECULAR BIOLOGY OF ETHANOL ACTION ON RECEPTORS
    George Breese; Fiscal Year: 2002
    ..Further, based upon structural analysis of ethanol's action on protein-protein inter-actions for the receptors, results may ultimately allow us to predict other protein-protein interactions influenced by ethanol. ..
  42. FACTORS REGULATING TYROSINE HYDROXYLASE GENE EXPRESSION
    Lorraine Iacovitti; Fiscal Year: 2002
    ..abstract_text> ..
  43. Alcoholism and Disease: Immune /Pathological Mechanisms
    Patricia Molina; Fiscal Year: 2002
    ..The proceedings of these symposia will be published and a summary report to the NIAAA will be prepared. ..
  44. Novel CRF antagonists for inflammation and pain
    MARK LINDNER; Fiscal Year: 2002
    ..Orally active forms of a small molecule CRF receptor would provide a novel therapeutic strategy for indications of acute and chronic inflammation and inflamatory pain. ..
  45. Immunoregulation by Endogenous Opioids
    Jan Moynihan; Fiscal Year: 2004
    ..Specific Aim 4: To determine if C57B1/6 mice, which do not have altered immune responses to KLH following stress odor exposure, have evidence of elevated endogenous opioids following odor exposure. ..
  46. Signaling By Nuclear G-Protein Coupled Receptors
    KAREN O MALLEY; Fiscal Year: 2005
    ..Direct nuclear calcium regulation represents a novel signaling strategy by which intracellular receptors such as mGlu5 may play a pivotal role in generating and shaping intracellular Ca2+ signals ..
  47. ASSAY FOR DETERMINING DRUG TOXICITY
    Chuenlei Parng; Fiscal Year: 2004
    ..abstract_text> ..
  48. Bladder Pain Gene Therapy with Pro-opiomelanocortin cDNA
    Naoki Yoshimura; Fiscal Year: 2004
    ..This research project is important to provide a solid basis for potential future clinical application. ..
  49. Gene Therapy, Neural Grafts & Parkinson's Disease
    DAVID YUREK; Fiscal Year: 2005
    ..These studies will also determine if combinations of viral vectors expressing different neurotrophic factors can be used to improve the therapeutic effects of dopamine grafts. ..
  50. Cardiotoxicity Drug Screening Using Zebrafish
    Chuenlei Parng; Fiscal Year: 2004
    ..Zebrafish drug screens can serve as an intermediate step between cell-based and mammalian testing, streamlining the drug development timeline. ..
  51. Ca permeable non-NMDAr: New spinal sensitization pathway
    Linda Sorkin; Fiscal Year: 2005
    ..We propose to investigate the effects of Ca-permeable non-NMDAr activation on ERK and CREB phosphorylation (using Western blots and immunohistochemistry), expression of c-fos and development of hyperalgesia. ..
  52. MOTOR ACTIONS OF CANNABINOIDS IN A PARKINSONS MODEL
    CLARA SANUDO PENA; Fiscal Year: 2002
    ..Behavioral, biochemical, and physiological studies will be conducted in parallel to test this possibility. It will also help integrate the cannabinergic system with the current knowledge of basal ganglia physiology. ..
  53. EFECTS OF STRESS IN IMMUNOCOMPROMISED HOSTS
    Jan Moynihan; Fiscal Year: 2003
    ..In turn, this will result in prolonged allograft survival. In contrast, the immunocompromised animal will have poorer immune responses to an opportunistic pathogen (HSV-1). ..
  54. Fetal & Adolescent Nicotine Effects on CNS 5HT Systems
    Theodore Slotkin; Fiscal Year: 2003
    ..abstract_text> ..
  55. ALPHA-1 ADRENERGIC SYSTEM IN ACTIVITY AND DEPRESSION
    Eric A Stone; Fiscal Year: 2010
    ..The research will likely identify the EPI/alpha-1 system as a new and important target for antidepressant and antistress medications ..
  56. Basal ganglia modulation of trigeminal intralaminar nuclei thalamic activity
    Eric Chudler; Fiscal Year: 2007
    ..These studies will help explain the complex sensory symptoms exhibited by patients with PD and may suggest new treatment strategies to alleviate such pain. [unreadable] [unreadable] [unreadable]..
  57. Estrogenic LXR Alpha Response /Cholesterol Homeostasis
    Phillip Kramer; Fiscal Year: 2003
    ..abstract_text> ..
  58. LENTIVIRAL DELIVERY OF GDNF AND BCL-2 IN PD MODEL
    Marina Emborg; Fiscal Year: 2003
    ..These studies will serve as the preclinical foundation to determine whether this in vivo method to deliver these potent trophic factor and antiapoptotic genes will be suitable for testing in patients with PD. ..
  59. Estrogenic Regulation of Inflammation Related to TMJD
    Phillip Kramer; Fiscal Year: 2006
    ..The function of estrogen receptors ER alpha and/or ER beta will be directly addressed pharmacologically (e.g., antiestrogen) and through mutation studies of the Fc gamma RIIIA promoter. ..
  60. Antidepressants and Fibroblast Growth Factor
    Italo Mocchetti; Fiscal Year: 2006
    ..Data from this proposal may help elucidate the therapeutic efficacy of antidepressants in affective disorders. [unreadable] [unreadable]..
  61. Neuronal transport of gp120
    Italo Mocchetti; Fiscal Year: 2005
    ..abstract_text> ..
  62. DRUGS AND DEVELOPMENT OF THE ADRENERGIC NERVOUS SYSTEM
    Theodore Slotkin; Fiscal Year: 2003
    ....
  63. INTERNET NEUROSCIENCE RESOURCE - PHASE II
    Eric Chudler; Fiscal Year: 2002
    ..An Internet version of the Neuroscience Resource will continue to be available. An on-line survey and analysis of daily use log files will determine how the Internet Neuroscience Resource is utilized. ..
  64. MECHANISMS OF CHLORPYRIFOS DEVELOPMENTAL NEUROTOXICITY
    Theodore Slotkin; Fiscal Year: 2004
    ..Molecular mechanisms of developmental neurotoxicity can be determined and linked to eventual alterations in behavioral performance. ..